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Improving the health of trans people: the need for good data
The health of transgender (trans) people (those with a 
gender identity which differs from the sex assigned to 
them at birth) is a major equity issue worldwide, with 
trans people experiencing poorer health outcomes 
than cis (non-trans) people.1 Data science approaches 
are improving public health, but trans people are at risk 
of not benefitting from these advances. Furthermore, 
specific ethical concerns regarding the application of 
such approaches to trans people’s data will require 
careful communication and engagement with the trans 
community.
High quality data are required to monitor health 
trends, assess health needs, and evaluate the effects 
of policies and other interventions. However, valid 
sources of quantitative data for trans people can be 
difficult to find. Population-based surveys are limited 
by the lack of standardised survey items used to identify 
trans respondents, and are often too small to provide 
meaningful samples of trans people.2 Research to 
inform health needs often relies on trans-specific service 
usage data,3 which can be of relatively poor quality and 
makes direct comparisons with cis populations difficult. 
This scarcity of data inclusion at the population and 
health-care system levels excludes trans people from 
health-care debates,4 potentially widening existing 
health inequalities. Additionally, there are considerable 
global inequalities—as far as we are aware, all previous 
national surveys of trans people’s health have been 
done in high-income rather than low-income or 
middle-income countries.1
Public health research and policies are increasingly 
harnessing routine administrative data sources, since 
primary data collection is expensive and often does 
not provide representative information. We argue 
that trans people could benefit from this approach; 
however, inherent challenges exist regarding the use of 
administrative datasets, which are unique to the trans 
population and might require the structure of existing 
datasets to change (panel). We acknowledge that our list 
is not exhaustive, and additional problems (particularly 
relevant to low-income and middle-income settings) 
include infrastructure, resources, and personnel 
constraints.
Given the ethical and legal complexities of the 
issues identified, public health professionals and 
epidemiologists considering the way forward must 
realise they need to engage with the trans community, 
as well as medical ethicists, legal professionals, and 
others. Despite ostensibly having protection under 
equality legislation in many parts of the world, many 
trans people continue to face discrimination at work and 
when accessing health-care services.1 Understandably, 
many trans people might not wish their trans status 
to be disclosed in routine data sources without their 
knowledge. A participatory approach with a strong 
emphasis on community engagement is essential to 
ensure their voices and concerns are heard and acted 
upon.7,8 Involvement of third sector organisations is likely 
to be of particular benefit because such organisations are 
often aware of the potential opportunities of harnessing 
data, and have been encouraging and facilitating data 
collection regarding sexual orientation and gender 
identity within the private sector.9
Panel: Challenges for using data science to improve health of transgender people
Binary classification
Most existing administrative datasets include only two sexes, excluding or misclassifying 
non-binary individuals (who have a gender identity which is neither exclusively male nor 
female). However, modifying these categories needs careful consideration, since changes 
can disrupt the ability to compare data over time and across data sources.
Ascertainment
Most administrative data do not include reference to a past sex to avoid outing people;5 
records of transgender (trans) people will be coded either as the sex they were assigned at 
birth or that with which they identify, with no identifier of their trans status.
Consent
Use of opt-in consent procedures, while probably acceptable to most people,6 might only 
reach those already in contact with trans-specific services. Identification of trans people 
within routine datasets without consent would require careful consideration of individual 
right to privacy to ensure acceptable safeguards are included.
Confidentiality
The likelihood of inadvertent disclosure and breach of confidentiality might be high. 
Trans people contribute approximately 0·3–0·5% of the world population,2 but far fewer 
are openly trans and in contact with services, making them a highly identifiable group 
within population datasets. Subgroup analysis (eg, considering trans men, trans women 
and non-binary individuals separately) would reduce numbers further, and disclosure risk 
must be considered.
Probabilistic matching
When linking individuals across databases, often only those deemed to have a high 
statistical likelihood of being the same person are matched and included in the analysis. 
Many trans people might have their sex or gender recorded in different ways across 
different datasets, so are more likely to be coded as a non-match and therefore omitted 
from the data analysed.
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Working with the trans community to establish 
frameworks for safe and acceptable usage and linkage 
of routine administrative data that consider the 
concerns of trans people has huge potential to improve 
understanding and service delivery for this population—
an example includes a Dutch study which used data 
linkage to more accurately quantify risk of breast cancer 
in the trans population.10 If the public health and wider 
research community do not act, while the rest of the 
population continue to reap the benefits of big data, trans 
people’s health might continue to be compromised.
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